Literature DB >> 11307050

Low-dose clozapine for the treatment of Parkinson's disease in a patient with schizophrenia.

G Orr1, H Munitz, H Hermesh.   

Abstract

Clozapine is known to be beneficial for the treatment of dopamine agonist-induced psychotic states in patients with Parkinson's disease (PD). Many reports have suggested that it may also be efficacious for the treatment of parkinsonian tremor. We describe a patient with schizophrenia in whom early-onset PD appeared after treatment with antipsychotic drugs. When the parkinsonian symptoms proved resistant to anticholinergic agents, we introduced a trial with up to 50 mg clozapine daily, which yielded a prompt and dramatic response. Thereafter, the parkinsonian symptoms reappeared each time the patient discontinued clozapine and rapidly disappeared on its repeat initiation. There was also a marked improvement in his psychotic and depressive symptoms. This report suggests that some patients with concomitant schizophrenia and PD-a difficult treatment challenge-may benefit from clozapine treatment alone for both disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11307050     DOI: 10.1097/00002826-200103000-00011

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  3 in total

1.  Schizophrenia and Parkinson's disease: challenges in management.

Authors:  Amin Gadit
Journal:  BMJ Case Rep       Date:  2011-12-20

2.  Bromocriptine and clozapine regulate dopamine 2 receptor gene expression in the mouse striatum.

Authors:  Anthony H Stonehouse; Frederick S Jones
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  Schizophrenia with Comorbid Idiopathic Parkinson's Disease: A Difficult Clinical Management Scenario.

Authors:  Sandeep Grover; Swapnajeet Sahoo; Manoj Kumar Goyal
Journal:  Indian J Psychol Med       Date:  2017 Nov-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.